Curasight’s CEO Ulrich Krasilnikoff comments:

"During the third quarter of 2025 and period after, Curasight continued to make significant clinical and strategic progress as we advance our mission to improve outcomes for patients with serious cancers through precision diagnostics and targeted radionuclide therapy. Our pipeline is moving forward on several key fronts. Most notably we are ready to enroll patients in the first clinical trial with our therapeutic platform uTREAT®, and remain on track to dose the first patient before the end of this year. We also continue to strengthen our intellectual property position and maintain momentum in our diagnostic platform uTRACE® phase II trial."

Q3 (2025-07-01 – 2025-09-30)

• Gross loss amounted to kDKK -12,076 (kDKK -6,135)
• Operating loss amounted to kDKK -13,545 (kDKK -8,099)
• Loss before tax amounted to kDKK -14,262 (kDKK -8,523)
• Loss for the period amounted to kDKK -19,204 (kDKK -10,737)
• Total assets amounted to kDKK 33,202 (kDKK 25,778)
• Equity ratio amounted to 52.6% (51.6%)
• Earnings per share amounted to DKK -0.28 (DKK -0.35)

Q1-Q3 (2025-01-01 – 2025-09-30)

• Gross loss amounted to kDKK -34,475 (kDKK -22,521)
• Operating loss amounted to kDKK -38,765 (kDKK -28,443)
• Loss before tax amounted to kDKK -41,420 (kDKK -30,002)
• Loss for the period amounted to kDKK -24,408 (kDKK -18,729)
• Total assets amounted to kDKK 33,202 (kDKK 25,778)
• Equity ratio amounted to 52.6% (51.6%)
• Earnings per share amounted to DKK -0.81 (DKK -1.25)

Numbers in parenthesis are the numbers from the same period in 2024.

For more information regarding Curasight, please contact:

Ulrich Krasilnikoff, CEO

Phone: +45 22 83 01 60

E-mail: uk@curasight.com

www.curasight.com